Eli Lilly: the promise of tirzepatide in obesity


(CercleFinance.com) – Eli Lilly announces that tirzepatide led to a reduction of up to 22.5% in the patient’s body mass (i.e. 24 kg in this case) after 72 weeks of treatment, as part of a phase III study.

Some 2539 participants were recruited in this study to assess the efficacy and safety of tirzepatide as a treatment for obesity or overweight with at least one comorbidity – but without diabetes.

‘Obesity is a chronic disease that often does not receive the same level of care as others despite its impact on physical, psychological and metabolic health,’ notes Louis J. Aronne, director of the Comprehensive Weight Control Center and expert in obesity at NewYork-Presbyterian/Weill Cornell Medical Center and study investigator.

‘Tirzepatide provided impressive weight reductions in this study, which could represent an important step forward in helping the patient-physician partnership to treat this complex disease,’ he added.

Copyright © 2022 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.





Facebook


LinkedIn


E-mail





Source link -85